CNNC Changchun Nuclear Medicine Base Obtains Production License

On August 28, the Jilin Provincial Drug Administration approved and issued the "Radiopharmaceutical Production License" to Changchun Atomic Hi-Tech Pharmaceutical Co., Ltd. (hereinafter referred to as "Changchun Hi-Tech"), a subsidiary of Atomic Hi-Tech under China Isotope & Radiation Corporation (CIRC). The acquisition of this license marks that Changchun Hi-Tech is now fully qualified for the production of technetium-labeled drugs.

Radiopharmaceuticals are characterized by short half-lives, high transportation requirements, and strict time sensitivity. Long-distance transportation not only increases transportation and time costs but also poses greater challenges to the stability and timeliness of clinical medication. With the production qualification, Changchun Hi-Tech will be able to complete the production and distribution of technetium-labeled drugs locally in Jilin Province, which will help improve the accessibility and reliability of clinical nuclear medicine drug supply in the Northeast region, benefiting public health and the well-being of the people.

Changchun Hi-Tech is an important nuclear medicine production base deployed by Atomic Hi-Tech in the Northeast region. The acquisition of production qualification marks a significant step for Atomic Hi-Tech in advancing its nationwide pharmaceutical center "13650" strategic layout. As a leading enterprise in the domestic radiopharmaceutical field, Atomic Hi-Tech has long been committed to building a nationwide nuclear medicine production and distribution network. By deploying production bases in key regions across the country, it achieves localized production and short-distance distribution of radiopharmaceuticals, thereby enhancing the supply efficiency and accessibility of nuclear medicine drugs nationwide. The production qualification of Changchun Hi-Tech further improves Atomic Hi-Tech's strategic layout in the Northeast region, forming regional synergy with existing production bases and building a nuclear medicine supply network with broader coverage, faster response, and more stable supply.